Abstract
EBV-encoded nuclear antigen-1 (EBNA-1) binding to a cis-acting viral DNA element, oriP, enables plasmids to persist in dividing human cells as multicopy episomes that attach to chromosomes during mitosis. In investigating the significance of EBNA-1 binding to mitotic chromosomes, we identified the basic domains of EBNA-1 within amino acids 1–89 and 323–386 as critical for chromosome binding. In contrast, the EBNA-1 C terminus (amino acids 379–641), which includes the nuclear localization signal and DNA-binding domain, does not associate with mitotic chromosomes or retain oriP plasmid DNA in dividing cell nuclei, but does enable the accumulation of replicated oriP-containing plasmid DNA in transient replication assays. The importance of chromosome association in episome maintenance was evaluated by replacing EBNA-1 amino acids 1–378 with cell proteins that have similar chromosome binding characteristics. High-mobility group-I amino acids 1–90 or histone H1–2 could substitute for EBNA-1 amino acids 1–378 in mediating more efficient accumulation of replicated oriP plasmid, association with mitotic chromosomes, nuclear retention, and long-term episome persistence. These data strongly support the hypothesis that mitotic chromosome association is a critical factor for episome maintenance. The replacement of 60% of EBNA-1 with cell protein is a significant step toward eliminating the need for noncellular protein sequences in the maintenance of episomal DNA in human cells.
EBV is a human herpesvirus that normally establishes latent infection and long-term persistence in human B lymphocytes (reviewed in ref. 1). Latent EBV infection is important in the etiology of lymphoid and epithelial cell malignancies (reviewed in ref. 1). The double-stranded EBV DNA genome usually persists in latently infected cell nuclei as a multicopy, circular episome (2, 3) that associates with chromosomes during mitosis (4). EBV episomes are replicated by cell DNA polymerase during S phase (5).
Much is known about the molecular mechanisms by which EBV episomes persist in human cells. Only two EBV components are required to stably maintain recombinant plasmids in dividing human cells: the cis-acting DNA segment oriP and the trans-acting EBV-encoded nuclear antigen-1 (EBNA-1) protein (6–8). EBNA-1 has a C-terminal domain that dimerizes on a specific 30-bp dyad DNA sequence that occurs repeatedly in oriP (9). Besides enabling the long-term persistence of oriP plasmid DNA, EBNA-1 augments the amount of replicated oriP plasmid DNA in transient replication assays and enhances transcription from promoters that are near oriP (7, 10, 11).
OriP has two essential components, DS and FR (10). DS is a dyad symmetry of four 30-bp EBNA-1 binding sites and is the functional origin for oriP plasmid DNA replication (9, 12, 13). FR is a family of 20 direct repeats of the 30-bp EBNA-1 binding sites and is the site at which plasmid DNA replication terminates (9, 12). FR mediates EBNA-1-dependent enhancement of transcription from nearby promoters (14). FR is also essential for the accumulation of replicated plasmid DNA in transient replication assays and for EBNA-1-dependent plasmid maintenance (15, 16). oriP plasmids can undergo limited replication even without EBNA-1, and the need for DS in plasmid maintenance can be satisfied by human DNA containing a functional origin of replication (17, 18).
EBNA-1 comprises 641 amino acids (Fig. 1). EBNA-1 amino acids 33–83, 328–382, and 379–386 are two arginine-rich basic domains and a nuclear localization signal (NLS), respectively. Amino acids 459–604 include the DNA-binding and dimerization domain (19, 20). Amino acids 90–327 are a glycine-alanine repeat domain that inhibits EBNA-1 degradation by proteasomes and recognition by cytotoxic T cells (21). Mutations in the EBNA-1 basic domains, NLS, or the DNA-binding domain have pleiotropic inhibiting effects on EBNA-1 functions in enhancing oriP-dependent transcription, in augmenting replicated DNA, and in enabling episome persistence (11). EBNA-1 binds diffusely to mitotic chromosomes (22) and is thought to mediate the random association of oriP-containing episomes with mitotic chromosomes.
The experiments reported here were undertaken to understand the role of EBNA-1 association with mitotic chromosomes in the persistence of oriP plasmids in human cells. To approach this question, we first identified the EBNA-1 amino acid sequences that bind to chromosomes.
Materials and Methods
Cell Lines, Transfection, and Immunoblot Analysis.
BJAB, an EBV-negative Burkitt lymphoma cell line, was cultured, transfected, used to derive cell lines stably expressing FLAG-tagged proteins, and analyzed by immunoblot for protein expression as described (23).
Plasmids.
Plasmids carrying the expression cassettes for enhanced green fluorescent protein (EGFP) fused EBNA-1 derivatives described in Fig. 1 were derived from pEGFPc1 (CLONTECH) and the BamHI-K fragment of EBV strain B95–8 DNA. The GE expression plasmid was constructed by inserting the 2.6-kb TfiI-HindIII fragment of BamHI-K between the BspEI and HindIII sites of pEGFPc1 after the corresponding TfiI and BspEI sites were filled in. The GN expression plasmid was constructed by insertion of the filled-in 1.2-kb TfiI-FokI fragment of BamHI-K into the filled-in BspEI site of pEGFPc1. For the construction of the other plasmids, DNAs encoding EBNA-1 amino acids 1–89, 323–386, or 379–641 were amplified from BamHI-K by PCR. GB2 or GC expression plasmid was constructed by the insertion of EBNA-1 amino acids 323–386 or 379–641 encoding DNA into XhoI and HindIII-cut pEGFPc1 or BglII and EcoRI-cut pEGFPc1, respectively. The GB1 expression plasmid was constructed by first inserting an oligonucleotide encoding the EBNA-1 NLS into BspEI- and BglII-cut pEGFPc1 and then EBNA-1 amino acid 1–89 encoding DNA into BglII- and EcoRI-cut pEGFPc1 with the NLS. The GB1B2 expression plasmid was constructed by inserting EBNA-1 amino acids 1–89 encoding DNA into BspEI- and BglII-cut GB2 expression plasmid. The DNA coding for high-mobility group-I (HMG-I) amino acids 1–90 was amplified by PCR from pCPC-IE (24; a gift from C. A. Panagiotidis, Aristotle University of Thessaloniki, Thessaloniki, Greece) and inserted between the BspEI and XhoI sites of GC expression plasmid to create GHMC expression plasmid. The DNA encoding full-length histone H1 (213 residues) was amplified by PCR from the IMAGE Consortium cDNA clone number 201127 (GenBank accession no. R98517) and similarly inserted into the GC expression plasmid to create the GH1C expression plasmid. Plasmids for expression of FLAG-epitope-tagged EBNA-1 derivatives were constructed from the plasmids expressing the EGFP-fused versions of the corresponding EBNA-1 derivatives by removing the NheI–BsrGI fragment that contains the EGFP coding sequence and inserting a double-stranded DNA oligonucleotide encoding the FLAG epitope. All recombinant plasmids were confirmed by dideoxynucleotide DNA sequencing.
The oriP plasmid, pOLP, was constructed by blunt-end insertions of the 2.3-kb DraI–StuI oriP fragment of EBV strain B95–8 DNA into the SmaI site of the pGL2 promoter (Promega) and the puromycin-resistant marker from pBabePuro into the BamHI site. The oriP-negative plasmid for control, pLP, is pOLP without the oriP insert. The plasmid used for producing fluorescent in situ hybridization (FISH) analysis probes, pOL, was constructed by replacing the XhoI–SmaI fragment of the vector pTre-Luc (CLONTECH) with the oriP DNA.
Southern Blot Analysis for Plasmid DNA.
After transfection with 50 μg of the indicated plasmid DNA, live cells were purified by NycoPrep 1.077 (Nycomed) fractionation, washed twice with PBS, incubated in growth medium for the indicated time, and washed again. Nonchromosomal DNA was isolated from washed cells with the bacterial alkaline lysis method (25). DNA from 106 cells was dissolved in 10 μl of 10 mM Tris⋅HCl (pH 7.9)/10 mM MgCl2/50 mM NaCl/1 mM DTT and incubated with 2–10 units of XhoI and 1 μg of RNase A for 2 h at 37°C to linearize the transfected plasmid DNA. To assay for replicated plasmid DNA, 5 units of DpnI was included. A standard Southern hybridization procedure (25) was used to detect plasmid DNA. Biotinylated probes were prepared from pOLP with the BioNick Labeling System (Life Technologies, Grand Island, NY), and the detection was performed with the PhotoGene Nucleic Acid Detection System (Life Technologies).
Confocal Microscopy.
Cells were treated with 0.5 μg/ml Colcemid for 4–6 h, washed with PBS, swollen in an hypotonic buffer (1% trisodium citrate/0.5 mM CaCl2/0.5 mM MgCl2), rapidly air-dried onto a microscopic slides, fixed with 4% formaldehyde in PBS for 15 min, permeabilized in 1% Triton X-100 in PBS, treated with 0.1 mg/ml RNase A in PBS for 30 min, stained with 1 μg/ml propidium iodide in PBS, and mounted with an antifade. Confocal microscopy used a Zeiss Axioskop microscope fitted with Nikon PCM-2000 confocal imaging hardware, Ar and HeNe laser sources, and c-imaging software (Compix, Cranberry Township, PA).
FISH Analysis for Plasmid DNA.
After transfection with 50 μg of pOLP plasmid DNA, cells were fractionated with Nycoprep; washed twice; incubated in growth medium for 72 h; treated with Colcemid; washed; swollen; air-dried onto microscopic slides; fixed; permeabilized; treated with RNase A; dehydrated through 70%, 90%, and 100% ethanol; and air-dried. Biotinylated probes were prepared from the 4.7-kb AatII–AseI oriP-firefly luciferase gene fragment of pOL and dissolved in in situ hybridization solution (Dako) at 5 ng/μl. Probes (4 μl) were added to each sample, and the samples were covered with a coverslip. Cellular and probe DNAs were denatured by incubating at 85°C for 5 min. Hybridization was for 2 days at 37°C in a moist chamber. After washing twice with 0.2× SSC (1× SSC = 0.15 M sodium chloride/0.015 M sodium citrate, pH 7) at 45°C for 30 min, plasmid signals were developed with the Fluorescein-TSA System (NEN). The samples were propidium-counterstained, mounted, and observed by confocal microscopy.
Results
EBNA-1 N-Terminal Basic Domains Associate with Mitotic Chromosomes, and C-Terminal DNA-Binding Domain Does Not.
The EBNA-1 domains that can associate with mitotic chromosomes were identified by fusing parts of the EBNA-1 ORF to the 3′ end of the EGFP ORF (Fig. 1). Codons for the EBNA-1 NLS (residues 379–386) (19) were included in all gene fusions. The EGFP-EBNA-1 fusion proteins were transiently expressed in BJAB, an EBV-negative Burkitt lymphoma cell line. As shown by immunoblot analyses with an anti-EGFP monoclonal antibody, each fusion protein was expressed as a single predominant protein, slightly larger than the expected size (Fig. 2A). In some experiments, small amounts of truncated proteins were also observed.
The interphase and metaphase distributions of EGFP and the EGFP-EBNA-1 fusion proteins were evaluated by confocal microscopy of fixed Colcemid-treated preparations in which DNA was stained with propidium. Composite images were recorded for cells that express similar levels of EGFP-EBNA-1 fusion proteins. In interphase cells, EGFP distributed evenly through the cell (Fig. 3A), whereas all EGFP-EBNA-1 fusion proteins described in Fig. 1 localized to nuclei, giving intensely yellow nuclear images on a black cytoplasmic background (Fig. 3 B and C; data not shown).
In mitotic cells, EGFP did not associate with the condensed chromosomes (Fig. 3D). The fusion protein of EGFP and wild-type EBNA-1 (GE) associated strongly and exclusively with chromosomes, resulting in intensely yellow chromosomes on a dark cellular background (Fig. 3E). EBNA-1 can be divided into N and C termini (amino acids 1–386 and 379–641, respectively) by truncation after or before the NLS. EGFP-EBNA-1 N terminus (GN) associated as strongly and exclusively with chromosomes as full-length EBNA-1 fusion (Fig. 3G). In contrast, EGFP-EBNA-1 C terminus (GC) did not associate with chromosomes at all (Fig. 3F). As shown in Fig. 1, the EBNA-1 N terminus has two basic domains (amino acids 33–83 and 328–382), flanking the glycine and alanine domain (amino acids 90–327). The EGFP-EBNA-1 fusion protein containing both basic domains but not the glycine-alanine stretch (GB1B2) associates as strongly with mitotic chromosomes as the wild-type EBNA-1 fusion (Fig. 3H). In contrast, fusion proteins that included only one basic domain, GB1 (Fig. 3I) and GB2 (Fig. 3J), associated only weakly with chromosomes, causing them to be orange in color, with some accentuation around the chromosomes and green fluorescence throughout the cell. Fusion proteins that contained one whole basic domain plus part of the other basic domain (i.e., amino acids 1–89 plus 348–386, 1–89 plus 323–365 and the NLS, 1–71 plus 323–386, or 56–89 plus 323–386) were intermediate in their chromosome association between those of GB1B2 and GB1 or GB2 (data not shown). Fusion proteins containing only a part of either basic domain (i.e., amino acids 1–71, 56–89, 323–365, or 348–379) and the NLS associated more weakly with chromosomes than did GB1 or GB2 (data not shown). These data indicate that both N-terminal basic domains are required for wild-type EBNA-1 association with mitotic chromosomes. Notably, the entire EBNA-1 C terminus, which includes the DNA-binding and dimerization domains, and NLS, cannot bind chromosomes.
HMG-I Amino Acids 1–90 (HMG-I 1–90) and Histone H1 Are Similar to EBNA-1 N Terminus in Mediating the Diffuse Association of the EBNA-1 C Terminus with Mitotic Chromosomes.
Although further dissection of the EBNA-1 basic domains could more precisely define the components critical for chromosome association and plasmid maintenance, these domains are also implicated in transcriptional activation, DNA looping and linking, and homo- and heterotypic protein–protein interactions (11, 26–31). Because specific mutations would therefore likely have pleiotropic effects, we chose an alternative approach; to replace the EBNA-1 chromosome associating domains with cellular proteins that were similar to EBNA-1 in the pattern and salt sensitivity of their association with chromosomes.
Chromosome pellets were prepared by hypotonic 1% Nonidet P-40 lysis of Colcemid-arrested EBNA-1-expressing BJAB cells as described (32). EBNA-1 began to elute from chromosomes in 0.1 M NaCl and was more than 50% eluted in 0.3 M NaCl (data not shown). Because histone H1 and HMG-I associate with mitotic chromosomes diffusely and elute from chromosomes at low (<0.5 M) salt (33, 34), they were further evaluated as surrogates for the EBNA-1 basic domains. HMG-I 1–90 (35) and histone H1 (36) are similar to the EBNA-1 basic domains (37) in their excess of basic amino acid but have no specific sequence alignment, as determined with align (DNAstar, Madison, WI) or blast software. As expected, HMG-I 1–90 or histone H1 fused to EGFP associated diffusely and intensely with mitotic chromosomes (data not shown). We therefore proceeded to make in-frame fusions of EGFP with HMG-I 1–90 or histone H1 and the EBNA-1 C terminus. These fusions were designated GHMC and GH1C, respectively. Expression of GHMC or GH1C in BJAB cells yielded proteins of the expected size (Fig. 2A). GHMC and GH1C localized to interphase nuclei (data not shown). As shown in Fig. 3 K and L, GHMC and GH1C associated diffusely and intensely with mitotic chromosomes. The association was strikingly similar to that of GE and different from that of GC, which did not associate with chromosomes. Thus, HMG-I 1–90 and histone H1 can replace the EBNA-1 basic domains in enabling the EBNA-1 C terminus to associate with mitotic chromosomes.
HMG-I 1–90 and Histone H1 Are Similar to EBNA-1 N Terminus in Enhancing EBNA-1 C Terminus-Mediated Early Accumulation of Replicated oriP Plasmid DNA.
The effect of EBNA-1 on the initial replication of oriP plasmids has usually been assayed by measuring replicated (DpnI-resistant) DNA that has accumulated in the presence or absence of EBNA-1 within 48–96 h of transfection (11, 13, 17, 31, 38). In most of these assays, EBNA-1 markedly increased the amount of replicated oriP plasmid DNA. The smallest EBNA-1 derivatives that had positive effects on the accumulation of replicated oriP plasmid DNA included at least one of the basic domains, the NLS and the DNA-binding domain (26, 38). Because replication is critical for persistence, we first investigated the extent to which HMG-I 1–90-EBNA-1 or histone H1-EBNA-1 C-terminal fusions are similar to EBNA-1 in enabling the accumulation of replicated oriP plasmid DNA. BJAB cell lines were derived that stably expressed similar levels of FLAG-tagged EBNA-1 (FE), FLAG-tagged EBNA-1 C terminus (FC), FLAG-tagged HMG-I 1–90 fused to the EBNA-1 C terminus (FHMC), or FLAG-tagged histone H1 fused to the EBNA-1 C terminus (FH1C) (Fig. 2B). These cells were transfected with oriP plasmid DNA. Nonchromosomal DNA was extracted from transfected cells 48 h after transfection and assayed for plasmid DNA by Southern blot analysis.
As estimated by the comparison of signal intensity with plasmid DNA standards (Fig. 4, lanes 1–5), the amounts of total intracellular plasmid DNA in the different transfected cells varied by less than 4-fold (Fig. 4, lanes 11–15). However, the amount and percentage of replicated DNA varied extensively among these cells. Replicated DNA was barely detectable in BJAB cells (Fig. 4, lane 10). In control lanes of similar experiments, no replicated plasmid DNA was detected in BJAB cells 48 h after the introduction of equivalent amounts of oriP-negative plasmid DNA (data not shown). Thus, low levels of oriP-dependent replication occurred in the absence of EBNA-1. Surprisingly, the percentage of replicated DNA in BJAB cells that express FC was 15-fold higher than in BJAB cells (Fig. 4, lane 9). Furthermore, the percentage of replicated DNA in the BJAB cells that express FE, FHMC, or FH1C was 3- to 4-fold higher than in FC-expressing cells (Fig. 4, lanes 6–8). In three separate experiments, the percentage of replicated oriP plasmid DNA in BJAB cells was 0.32 ± 0.13, and in FC-, FE-, FHMC-, or FH1C-expressing cells it was 4.2 ± 1.2, 13.4 ± 1.2, 11.4 ± 1.0, or 12.1 ± 2.1, respectively. Therefore, the EBNA-1 C terminus substantially increases the accumulation of replicated oriP plasmid DNA in the first 48 h after transfection, and the EBNA-1 N terminus further enhances this effect. HMG-I 1–90 or histone-H1 can functionally substitute for the EBNA-1 N terminus in the initial accumulation of replicated DNA.
EBNA-1 N Terminus, HMG-I 1–90, or Histone-H1 Is Required for Tethering oriP Plasmids to Mitotic Chromosomes and Interphase Nuclei.
BJAB cells stably expressing various EBNA-1-derived fusion proteins were transfected with oriP plasmid DNA. After 3 days, cells were processed for FISH analysis with the use of plasmid DNA probes that were detected with fluorescein-conjugated tyramide. Cell DNA was stained with propidium. Typical results are shown in Fig. 5. In FE-expressing cells, most oriP plasmids localized to interphase nuclei and mitotic chromosomes; the plasmid signals were yellow on the red cell DNA background (Fig. 5 A and B). Very little plasmid DNA was in the cytoplasm. In contrast, oriP plasmid signals were green and extranuclear in FC-expressing interphase cells and were not associated with mitotic chromosomes (Fig. 5 C and D). The FISH signals were consistently surprisingly low for FC-expressing cells and lower than estimates by Southern blot analysis (data not shown). The low FISH signals may be due to plasmid loss from the cytoplasm during the FISH procedure, as has been described (39). These results indicate that the EBNA-1 N terminus is necessary for tethering the EBNA-1 C terminus with attached oriP plasmids to mitotic chromosomes and for retaining oriP plasmids in interphase nuclei. FHMC and FH1C were indistinguishable from FE in localizing oriP plasmid DNA to interphase nuclei and mitotic chromosomes (Fig. 5 E–H). Histone H1 or HMG-1–90 can therefore substitute for the EBNA-1 N terminus in tethering oriP-based plasmids to mitotic chromosomes and interphase nuclei. These data therefore indicate that chromosome association is an essential activity of the EBNA-1 N terminus in tethering oriP plasmids to mitotic chromosomes and in partitioning episomes to progeny interphase nuclei.
Chimeric HMG-I 1–90-EBNA-1 and Histone H1-EBNA-1 C Terminus Fusion Proteins Are Similar to EBNA-1 in Long-Term oriP Plasmid Maintenance.
Having established that HMG-I 1–90 and histone H1 can substitute for the EBNA-1 N terminus in enhancing the accumulation of replicated oriP plasmid DNA 48 h after transfection and in tethering oriP plasmids to mitotic chromosomes and interphase nuclei, we proceeded to evaluate their capacity for long-term episome maintenance. Two days after transfection with oriP plasmid DNA that includes a puromycin-resistance marker, transfected cells expressing the various FLAG-tagged proteins were put under puromycin selection at a low initial density (5 × 104 cells per ml). Consistent with the ability of FE, FHMC, and FH1C to enable efficient oriP-based plasmid persistence, FE-, FHMC-, or FH1C-transfected cells in puromycin grew to saturation (106 cells per ml) in 4–5 days, whereas FC-transfected cells in puromycin required 9–10 days to grow to saturation. Transfected cells were grown in puromycin for 31 days at cell densities maintained between 5 × 104 and 106 cells per ml. Nonchromosomal DNA was isolated from these cells and analyzed for plasmid DNA (Fig. 6). Plasmid DNA was detected in FE-expressing cells and was equivalent to about 30 copies per cell (Fig. 6, lane 5). No plasmid DNA persisted in cells expressing FC (lane 6). The oriP puromycin plasmid was integrated into cell DNA in the FC-expressing cells. Importantly, oriP plasmid DNA was detected in cells expressing FHMC and FH1C and was as abundant as in FE-expressing cells (Fig. 6, lanes 7 and 8). These data indicate that HMG-I 1–90 or histone H1 can substitute for the EBNA-1 chromosome-binding domains and enable long-term persistence of oriP-based plasmids in human cells, an ability that the EBNA-1 C terminus, which includes DNA-binding and dimerization domains and the NLS, lacks. In control experiments, an otherwise isogeneic plasmid that lacks oriP was transfected into FE-, FHMC-, FH1C-, and FC-expressing cells, and the cells were cultured in medium containing puromycin. The efficiencies of all transfections were similar as estimated from plasmid-borne luciferase expression 2 days after transfection (data not shown). However, puromycin-resistant cell lines grew out after only 9–10 days. Plasmid episomes could not be detected in any of the cells after 1 month in selective medium (Fig. 6, lanes 9–11). These data confirm the oriP dependence of FE-, FHMC-, and FH1C-mediated episome maintenance.
Discussion
These experiments indicate that EBNA-1 has two separate components that mediate the long-term persistence of oriP-dependent episomes in human cells. The EBNA-1 C terminus mediates specific binding to oriP DNA and increases the initial accumulation of replicated DNA, but cannot mediate mitotic chromosome association, efficient nuclear retention, or episome persistence. The EBNA-1 N terminus is necessary for mitotic chromosome association, more efficient accumulation of replicated oriP DNA, and long-term episome persistence.
Most of EBNA-1 other than the glycine-alanine repeat domain was previously known to be important for the early accumulation of replicated oriP plasmid DNA (transient replication), enhanced transcription, and long-term episome maintenance (11). However, the specific role of various EBNA-1 domains in early replicated plasmid DNA accumulation and long-term persistence was not evident. Some of the specific roles of the basic domains (amino acids 33–83 and 328–382) have been identified. In one study, deletion of EBNA-1 amino acids 325–376 had almost no effect on initial DNA replication but nearly eradicated episome persistence (31). The basic domains are also implicated in the looping between EBNA-1 bound to FR and DS, in linking among EBNA-1 molecules and in interactions with cellular proteins, one of which, EBP2, is associated with mitotic chromosomes (27–31, 40).
One important point of departure for the experiments described here is that the C-terminal domain of EBNA-1 enabled the initial accumulation of replicated oriP plasmid DNA, and the N terminus increased the efficiency. Replicated plasmid DNA was assayed 48 h after transfection, and the cells could divide only once or twice in this period. Some replicated oriP plasmid DNA was present in cells without any EBNA-1 expression, supporting the recent report that oriP is a cis-acting origin for DNA synthesis, even in the absence of EBNA-1 (17). However, the EBNA-1 C terminus consistently increased the amount of replicated DNA by more than 10-fold, and wild-type EBNA-1, HMG-I 1–90-EBNA-1 C terminus, and histone H1-EBNA-1 C terminus enabled the accumulation of 3- to 4-fold more replicated oriP DNA than the EBNA-1 C terminus. The positive effect of EBNA-1 C terminus on initial replicated DNA accumulation could be due to an effect on oriP DNA replication or nuclear retention. Either could result in the observed increase in accumulation of replicated DNA. Distinguishing between a role for EBNA-1 C terminus in nuclear retention versus replication is important for further understanding the role of the C terminus in episome maintenance. The added effect of HMG-I 1–90, histone H1, or EBNA-1 N terminus is most likely due to their role in tethering oriP DNA to mitotic chromosomes and partitioning oriP DNA to postmitotic interphase nuclei. Histone H1 in particular is highly unlikely to have any specific effect on assembly of DNA replication machinery. HMG-I 1–90, histone H1, or EBNA-1 N terminus also enabled the long-term persistence of oriP plasmids. We estimate the rate of loss of oriP DNA from cells maintained under nonselective conditions 4–10 days after plasmid introduction to be 15% per cell division from cells expressing wild-type EBNA-1 and 50% from cells expressing EBNA-1 C terminus or no EBNA-1 (data not shown). Whereas the absolute numbers will vary with the precise plasmid and experimental design, the EBNA-1 N terminus increases episome retention, whereas the EBNA-1 C terminus clearly lacks important components of that activity, as is also evident from the interphase FISH data presented here.
Our data indicate that mitotic chromosome association is mediated by the combined effect of both EBNA-1 basic domains. A recently study using similar approaches also showed that the EBNA-1 basic domains bind chromosomes (41). In contrast to our results, however, this study concluded that individual basic regions of EBNA-1 (amino acids 8–67, 70–89, and 328–365) could mediate intense chromosome association in a manner similar to that of full-length wild-type EBNA-1. Another recent study noted that a deletion of EBNA-1 amino acids 325–376 substantially weakened the association of EBNA-1 with fixed mitotic chromosomes, which is consistent with our data (40).
The observations here that the EBNA-1 N terminus is essential for tying oriP containing plasmids to mitotic chromosomes, for efficient replicated plasmid DNA accumulation, and for long-term episome persistence lends considerable support to the hypothesis that chromosome association is critical for episome persistence in dividing cells. Recently, bovine papillomavirus type 1 E2 protein has been found to have a chromosome-associating domain that is critical for the maintenance of bovine papillomavirus type 1-derived episomes (42, 43). The Kaposi sarcoma herpesvirus nuclear protein LANA also diffusely associates with mitotic chromosomes and mediates the long-term episome persistence of plasmids that include Kaposi sarcoma herpesvirus terminal-repeat DNA (44).
The evidence presented here for the importance of chromosome association in episome persistence includes not only the necessity of the EBNA-1 N terminus for both activities, but also the adequacy of substitution of EBNA-1 N terminus with HMG-I 1–90 or with histone H1. When fused with the EBNA-1 C terminus, HMG-I 1–90 and histone H1 tethered oriP plasmids to chromosomes and interphase nuclei and mediated long-term episome persistence with efficiencies that were similar to that of EBNA-1 N terminus. Importantly, the only similarities of HMG-I 1–90 and histone H1 to EBNA-1 N terminus is a high content of basic amino acids and the association with mitotic chromosomes (33, 35–37). Furthermore, much of the chromosome-associating activity of histone H1 and HMG-I is attributed to non-sequence-specific interaction with DNA in the case of histone H1 (reviewed in ref. 45) or A-T-rich sequence interaction in the case of HMG-I (33).
EBNA-1 molecules can link separate oriP DNAs by homotypic interaction through the N termini (27, 28). This observation has raised the possibility that EBNA-1 might link oriP episomes to EBNA-1 recognition sites on chromosomal DNA by the same mechanism (26). However, the data presented here and in another recently reported study (41) indicate that the EBNA-1 DNA binding domain does not bind to mitotic chromosomes. Instead, the EBNA-1 N-terminal basic domains tie the EBNA-1 C terminus with its bound oriP plasmid DNA to mitotic chromosomes. The ability of HMG-I 1–90 and histone H1 to substitute for the EBNA-1 N terminus is further strong evidence for a direct role in tethering to chromosome of the EBNA-1 N terminus.
Despite the differences among the EBNA-1 N terminus, HMG-I 1–90, and histone H1, their chromosome-associating characteristics may also enable episome maintenance or transcription through interactions in interphase nuclei. Consistent with this notion, we have found that the HMG-I 1–90 or histone H1 chimeric fusions with EBNA-1-C terminus have at least 30% of the wild-type EBNA-1 500-fold enhancing effect on luciferase transcription from a transfected plasmid that has oriP upstream of a basal promoter, whereas the EBNA-1 C terminus has a less than 1% effect (data not shown).
The functional substitution of 60% (N terminus) of EBNA-1 with HMG-I 1–90 or histone H1 has implications for the design of episome vectors for gene therapy. The chimeric HMG-I-EBNA-1 and histone H1-EBNA-1 fusion proteins are highly competent for the establishment and long-term maintenance of high copy episomes. These chimeric proteins have at least three advantages over wild-type EBNA-1. First, because the amount of foreign protein sequence has been substantially reduced, the chimeric proteins should be less immunogenic. Second, EBNA-1 has been implicated in the predisposition of lymphocytes to lymphoma (46). To the extent that the EBNA-1 N terminus is involved in the putative effects, substitution of EBNA-1 N terminus with histone H1 is less likely to affect cell growth or survival. Third, the substitution of 60% of EBNA-1 with HMG-I 1–90 or histone H1 formally opens the possibility of substituting the rest of EBNA-1 with cellular proteins that have appropriate activities necessary for replicated oriP plasmid accumulation and episome persistence. For example, the cell protein Kid specifically binds to the EBNA-1 cognate DNA sequence (47, 48) and may substitute for all or part of the activity of EBNA-1 C terminus. An alternative approach would be to substitute for EBNA-1 by replacing the repeats of EBNA-1 cognate site in oriP with repeats of the cognate DNA sequence of a cell chromosomal protein. CENP-B, for example, might tether a plasmid with its cognate DNA sequence (49) to mitotic chromosomes and ensure long-term persistence without the need for heterologous expression of an EBNA-1 surrogate.
Acknowledgments
We acknowledge George Mosialos for the initial suggestion of a replacement genetic approach; Mary Ballestas for helpful discussions and technical guidance of the FISH analysis; Fred Wang for general guidance; and Robert Kingston, Martin Gorovsky, and Arthur Skoultchi for advice about chromosomal proteins. This research was supported by Research Grant CA47006 from the National Cancer Institute of the U.S. Public Health Service. M.-S.K. is supported in part by the Korean Research Foundation Grant awarded in the program year 1997.
Abbreviations
- EBV
Epstein–Barr virus
- EBNA-1
EBV-encoded nuclear antigen-1
- HMG-I
high-mobility group-I
- NLS
nuclear localization signal
- EGFP
enhanced green fluorescent protein
- FISH
fluorescent in situ hybridization
- FE
FLAG-tagged EBNA-1
- FC
FLAG-tagged EBNA-1 C terminus
- FHMC
FLAG-tagged HMG-I 1–90 fused to the EBNA-1 C terminus
- FH1C
FLAG-tagged histone H1 fused to the EBNA-1 C terminus
Footnotes
Article published online before print: Proc. Natl. Acad. Sci. USA, 10.1073/pnas.031584698.
Article and publication date are at www.pnas.org/cgi/doi/10.1073/pnas.031584698
References
- 1.Rickinson A B, Kieff E. In: Fields Virology. Fields B N, Knipe D M, Howley P M, editors. Philadelphia: Lippincott; 1996. pp. 2397–2446. [Google Scholar]
- 2.Nonoyama M, Pagano J S. Nat New Biol. 1972;238:169–171. doi: 10.1038/newbio238169a0. [DOI] [PubMed] [Google Scholar]
- 3.Lindahl T, Adams A, Bjursell G, Bornkamm G W, Kaschka-Dierich C, Jehn U. J Mol Biol. 1976;102:511–530. doi: 10.1016/0022-2836(76)90331-4. [DOI] [PubMed] [Google Scholar]
- 4.Harris A, Young B D, Griffin B E. J Virol. 1985;56:328–332. doi: 10.1128/jvi.56.1.328-332.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Adams A. J Virol. 1987;61:1743–1746. doi: 10.1128/jvi.61.5.1743-1746.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Yates J, Warren N, Reisman D, Sugden B. Proc Natl Acad Sci USA. 1984;81:3806–3810. doi: 10.1073/pnas.81.12.3806. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Yates J L, Warren N, Sugden B. Nature (London) 1985;313:812–815. doi: 10.1038/313812a0. [DOI] [PubMed] [Google Scholar]
- 8.Lupton S, Levine A J. Mol Cell Biol. 1985;5:2533–2542. doi: 10.1128/mcb.5.10.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Rawlins D R, Milman G, Hayward S D, Hayward G S. Cell. 1985;42:859–868. doi: 10.1016/0092-8674(85)90282-x. [DOI] [PubMed] [Google Scholar]
- 10.Reisman D, Yates J, Sugden B. Mol Cell Biol. 1985;5:1822–1832. doi: 10.1128/mcb.5.8.1822. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Yates J L, Camiolo S M. In: Eukaryotic DNA Replication, Cancer Cells. Kelley T, Stillman B, editors. Vol. 6. Plainview, NY: Cold Spring Harbor Lab. Press; 1988. pp. 197–205. [Google Scholar]
- 12.Gahn T A, Schildkraut C L. Cell. 1989;58:527–535. doi: 10.1016/0092-8674(89)90433-9. [DOI] [PubMed] [Google Scholar]
- 13.Harrison S, Fisenne K, Hearing J. J Virol. 1994;68:1913–1925. doi: 10.1128/jvi.68.3.1913-1925.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Reisman D, Sugden B. Mol Cell Biol. 1986;6:3838–3846. doi: 10.1128/mcb.6.11.3838. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wysokenski D A, Yates J L. J Virol. 1989;63:2657–2666. doi: 10.1128/jvi.63.6.2657-2666.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chittenden T, Lupton S, Levine A J. J Virol. 1989;63:3016–3025. doi: 10.1128/jvi.63.7.3016-3025.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Aiyar A, Tyree C, Sugden B. EMBO J. 1998;17:6394–6403. doi: 10.1093/emboj/17.21.6394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Krysan P J, Haase S B, Calos M P. Mol Cell Biol. 1989;9:1026–1033. doi: 10.1128/mcb.9.3.1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Ambinder R F, Mullen M A, Chang Y N, Hayward G S, Hayward S D. J Virol. 1991;65:1466–1478. doi: 10.1128/jvi.65.3.1466-1478.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Chen M R, Middeldorp J M, Hayward S D. J Virol. 1993;67:4875–4885. doi: 10.1128/jvi.67.8.4875-4885.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Levitskaya J, Sharipo A, Leonchiks A, Ciechanover A, Masucci M G. Proc Natl Acad Sci USA. 1997;94:12616–12621. doi: 10.1073/pnas.94.23.12616. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ohno S, Luka J, Lindahl T, Klein G. Proc Natl Acad Sci USA. 1977;74:1605–1609. doi: 10.1073/pnas.74.4.1605. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Devergne O, McFarland E C, Mosialos G, Izumi K M, Ware C F, Kieff E. J Virol. 1998;72:7900–7908. doi: 10.1128/jvi.72.10.7900-7908.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Panagiotidis C A, Silverstein S J. Virology. 1999;256:64–74. doi: 10.1006/viro.1999.9607. [DOI] [PubMed] [Google Scholar]
- 25.Sambrook J, Fritsch E F, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd Ed. Plainview, NY: Cold Spring Harbor Lab. Press; 1989. [Google Scholar]
- 26.Mackey D, Sugden B. Mol Cell Biol. 1999;19:3349–3359. doi: 10.1128/mcb.19.5.3349. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Mackey D, Sugden B. J Biol Chem. 1997;272:29873–29879. doi: 10.1074/jbc.272.47.29873. [DOI] [PubMed] [Google Scholar]
- 28.Avolio-Hunter T M, Frappier L. Nucleic Acids Res. 1998;26:4462–4470. doi: 10.1093/nar/26.19.4462. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Wang Y, Finan J E, Middeldorp J M, Hayward S D. Virology. 1997;236:18–29. doi: 10.1006/viro.1997.8739. [DOI] [PubMed] [Google Scholar]
- 30.Kim A L, Maher M, Hayman J B, Ozer J, Zerby D, Yates J L, Lieberman P M. Virology. 1997;239:340–351. doi: 10.1006/viro.1997.8874. [DOI] [PubMed] [Google Scholar]
- 31.Shire K, Ceccarelli D F, Avolio-Hunter T M, Frappier L. J Virol. 1999;73:2587–2595. doi: 10.1128/jvi.73.4.2587-2595.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Adolph K W. Chromosoma. 1980;76:23–33. doi: 10.1007/BF00292223. [DOI] [PubMed] [Google Scholar]
- 33.Disney J E, Johnson K R, Magnuson N S, Sylvester S R, Reeves R. J Cell Biol. 1989;109:1975–1982. doi: 10.1083/jcb.109.5.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Lund T, Holtlund J, Laland S G. FEBS Lett. 1985;180:275–279. doi: 10.1016/0014-5793(85)81085-1. [DOI] [PubMed] [Google Scholar]
- 35.Johnson K R, Lehn D A, Reeves R. Mol Cell Biol. 1989;9:2114–2123. doi: 10.1128/mcb.9.5.2114. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Eick S, Nicolai M, Mumberg D, Doenecke D. Eur J Cell Biol. 1989;49:110–115. [PubMed] [Google Scholar]
- 37.Arrand J R, Rymo L, Walsh J E, Bjorck E, Lindahl T, Griffin B E. Nucleic Acids Res. 1981;9:2999–3014. doi: 10.1093/nar/9.13.2999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Kirchmaier A L, Sugden B. J Virol. 1997;71:1766–1775. doi: 10.1128/jvi.71.3.1766-1775.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Ilves I, Kivi S, Ustav M. J Virol. 1999;73:4404–4412. doi: 10.1128/jvi.73.5.4404-4412.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Wu H, Ceccarelli D F J, Frappier L. EMBO Rep. 2000;1:140–144. doi: 10.1093/embo-reports/kvd026. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Marechal V, Dehee A, Chikhi-Brachet R, Piolot T, Coppey-Moisan M, Nicolas J C. J Virol. 1999;73:4385–4392. doi: 10.1128/jvi.73.5.4385-4392.1999. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Lehman C W, Botchan M R. Proc Natl Acad Sci USA. 1998;95:4338–4343. doi: 10.1073/pnas.95.8.4338. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Skiadopoulos M H, McBride A A. J Virol. 1998;72:2079–2088. doi: 10.1128/jvi.72.3.2079-2088.1998. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Ballestas M E, Chatis P A, Kaye K M. Science. 1999;284:641–644. doi: 10.1126/science.284.5414.641. [DOI] [PubMed] [Google Scholar]
- 45.Wolffe A P. Int J Biochem Cell Biol. 1997;29:1463–1466. doi: 10.1016/s1357-2725(97)00026-5. [DOI] [PubMed] [Google Scholar]
- 46.Wilson J B, Bell J L, Levine A J. EMBO J. 1996;15:3117–3126. [PMC free article] [PubMed] [Google Scholar]
- 47.Zhang S, Nonoyama M. Proc Natl Acad Sci USA. 1994;91:2843–2847. doi: 10.1073/pnas.91.7.2843. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Tokai N, Fujimoto-Nishiyama A, Toyoshima Y, Yonemura S, Tsukita S, Inoue J, Yamamota T. EMBO J. 1996;15:457–467. [PMC free article] [PubMed] [Google Scholar]
- 49.Masumoto H, Masukata H, Muro Y, Nozaki N, Okazaki T. J Cell Biol. 1989;109:1963–1973. doi: 10.1083/jcb.109.5.1963. [DOI] [PMC free article] [PubMed] [Google Scholar]